NEW
YORK, Dec. 18, 2023 /PRNewswire/ -- The Gross
Law Firm issues the following notice to shareholders of Outlook
Therapeutics, Inc..
Shareholders who purchased shares of OTLK during the class
period listed are encouraged to contact the firm regarding possible
lead plaintiff appointment. Appointment as lead plaintiff is not
required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/outlook-loss-submission-form/?id=60148&from=4
CLASS PERIOD: December 29,
2022 to August 29, 2023
ALLEGATIONS: The complaint alleges that
during the class period, Defendants issued materially false and/or
misleading statements and/or failed to disclose that: (i) there was
a lack of substantial evidence supporting the Company's lead
product candidate, ONS-5010, as a treatment for wet age-related
macular degeneration; (ii) Outlook and/or its manufacturing partner
had deficient chemistry manufacturing and controls and other
manufacturing issues for ONS-5010, which remained unresolved at the
time the ONS-5010 biologics license application ("BLA") was
resubmitted to the U.S. Food and Drug Administration ("FDA"); (iii)
as a result of all the foregoing, the FDA was unlikely to approve
the ONS-5010 BLA in its present form; (iv) accordingly, ONS-5010's
regulatory and commercial prospects were overstated; and (v) as a
result, the Company's public statements were materially false and
misleading at all relevant times.
DEADLINE: January 2, 2024
Shareholders should not delay in registering for this class action.
Register your information here:
https://securitiesclasslaw.com/securities/outlook-loss-submission-form/?id=60148&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you register as a
shareholder who purchased shares of OTLK during the timeframe
listed above, you will be enrolled in a portfolio monitoring
software to provide you with status updates throughout the
lifecycle of the case. The deadline to seek to be a lead plaintiff
is January 2, 2024. There is no cost
or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally
recognized class action law firm, and our mission is to protect the
rights of all investors who have suffered as a result of deceit,
fraud, and illegal business practices. The Gross Law
Firm is committed to ensuring that companies adhere to responsible
business practices and engage in good corporate citizenship. The
firm seeks recovery on behalf of investors who incurred losses when
false and/or misleading statements or the omission of material
information by a company lead to artificial inflation of the
company's stock. Attorney advertising. Prior results do not
guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
View original content to download
multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-outlook-therapeutics-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-january-2-2024--nasdaq-otlk-302017218.html
SOURCE Gross Law Firm